Pular para o conteúdo principal
Ranking Invest

ALVO - Alvotech

Segmento: HealthcareAlvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Análise Ranking Invest

Valor de Mercado
-8,40%
$ 1.64 Bi
IVR
-0.83Índice proprietário de comparação relativa: -0,83.
IVR2
-0.57Leitura proprietária complementar: -57%.
MLL
-0.57Leitura proprietária complementar: -57%.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

-$ 302.29 Mi

Dívida Líquida

$ 1.19 Bi

L4T

$ 96.55 Mi

MM4T

15.02%

Indicadores Básicos

ROE

-31.94%

Índices de Previsibilidade

Receita Líquida

G2.30

Lucro

F2.08

Margem

E1.31

Índices de Tendência

Receita Líquida

B8.71

Lucro

D-0.53

Margem

B5.03

Índices de Endividamento

DIV/PAT

-3.93

DIV/L4T

12.31

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.